Single CD4 Test with 250 Cells/Mm(3) Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria by Gilks, CF et al.
A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts
Viral Suppression in HIV-Infected Adults Failing First-Line
Therapy by Clinical Criteria
Charles F. Gilks1., A. Sarah Walker2*., Paula Munderi3, Cissy Kityo4, Andrew Reid5, Elly Katabira6,
Ruth L. Goodall2, Heiner Grosskurth3, Peter Mugyenyi4, James Hakim5, Diana M. Gibb2, on behalf of the
DART Virology Group and Trial Team
1Department of Medicine, Imperial College, London, United Kingdom, 2Medical Research Council Clinical Trials Unit, London, United Kingdom, 3Medical Research
Council/ Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda, 4 Joint Clinical Research Centre, Kampala, Uganda, 5Clinical Research Centre,
University of Zimbabwe, Harare, Zimbabwe, 6 Infectious Diseases Institute, Mulago, Uganda
Abstract
Background: In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the
public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger
regimen switch may result in unnecessary use of costly second-line therapy. Our objective was to identify CD4 threshold
values to confirm clinically-determined ART failure when VL is unavailable.
Methods: 3316 HIV-infected Ugandan/Zimbabwean adults were randomised to first-line ART with Clinically-Driven (CDM,
CD4s measured but blinded) or routine Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s) in the DART trial. CD4 at
switch and ART failure criteria (new/recurrent WHO 4, single/multiple WHO 3 event; LCM: CD4,100 cells/mm3) were
reviewed in 361 LCM, 314 CDM participants who switched over median 5 years follow-up. Retrospective VLs were available
in 368 (55%) participants.
Results: Overall, 265/361 (73%) LCM participants failed with CD4,100 cells/mm3; only 7 (2%) switched with CD4$250 cells/
mm3, four switches triggered by WHO events. Without CD4 monitoring, 207/314 (66%) CDM participants failed with WHO 4
events, and 77(25%)/30(10%) with single/multiple WHO 3 events. Failure/switching with single WHO 3 events was more
likely with CD4$250 cells/mm3 (28/77; 36%) (p = 0.0002). CD4 monitoring reduced switching with viral suppression: 23/187
(12%) LCM versus 49/181 (27%) CDM had VL,400 copies/ml at failure/switch (p,0.0001). Amongst CDM participants with
CD4,250 cells/mm3 only 11/133 (8%) had VL,400copies/ml, compared with 38/48 (79%) with CD4$250 cells/mm3
(p,0.0001).
Conclusion: Multiple, but not single, WHO 3 events predicted first-line ART failure. A CD4 threshold ‘tiebreaker’ of $250
cells/mm3 for clinically-monitored patients failing first-line could identify ,80% with VL,400 copies/ml, who are unlikely to
benefit from second-line. Targeting CD4s to single WHO stage 3 ‘clinical failures’ would particularly avoid premature, costly
switch to second-line ART.
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Introduction
Most HIV-infected individuals on antiretroviral therapy (ART)
in low/middle-income countries are treated following the WHO
public health approach [1]: the public sector provides one
standard first-line regimen, with alternative drug substitutions for
anti-tuberculosis co-therapy/toxicity; when first-line failure occurs,
the patient switches to a standard boosted-protease inhibitor (bPI)-
based second-line regimen. Current WHO guidelines[2] define
failure by virological (.5,000 copies/ml), immunological (CD4
below pre-therapy baseline; 50% fall from on-treatment peak;
persistently ,100 cells/mm3) or clinical criteria after 6 months on
ART. Low-income countries differ in their ability to provide
laboratory tests to identify first-line failure and support routine
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follow-up; if available at all, CD4 testing is most common with
viral loads (VL) sometimes used to confirm clinical/immunological
failure[2]. Routine virological monitoring is rarely available or
feasible[3]. Such approaches differ markedly from individualised
management in high-income countries, where routine VL
monitoring is used to modify initial or subsequent therapy and
many drugs are available.
WHO 2010 definition of clinical failure includes WHO 4 and
certain WHO stage 3 conditions. Without VLs, it is strongly
recommended that immunological criteria confirm clinical failure
(noting moderate quality of evidence), but no CD4 threshold value
is proposed. We therefore evaluated switches from first to second-
line ART in the DART trial[4,5], particularly considering the
unique group randomised to clinically-driven monitoring (CDM)
and managed without CD4 counts, but for whom CD4s (and some
VLs) were available for retrospective analysis. The aims were to
investigate the characteristics of immunological/clinical failures
determined without routine VL monitoring and with or without
routine real-time CD4 monitoring; and to identify optimal CD4
thresholds to confirm clinical failure and switch to second-line
ART when VLs are unavailable.
Materials and Methods
Ethics statement
Informed written consent was obtained from each participant
and the trial was approved by ethics committees in Uganda,
Zimbabwe and the UK.
DART was a randomised controlled trial comparing routine
Laboratory (CD4 and toxicity) plus Clinical Monitoring (LCM)
with CDM in 3316 symptomatic (WHO stage 2/3/4) HIV-
infected ART-naı¨ve adults initiating combination ART with
CD4,200 cells/mm3 in Uganda/Zimbabwe
(ISCRTN13968779)[4]. Participants were enrolled January
2003-October 2004 and initiated co-formulated zidovudine/
lamivudine with either tenofovir, abacavir or nevirapine[6].
All participants were reviewed 4-weekly by a nurse, and saw a
doctor and had routine lymphocyte subsets (CD4, CD8) at
screening, weeks 4 and 12, then 12-weekly. All results from LCM
participants were returned to clinicians, whereas for CDM
participants CD4 counts were measured but never returned. For
all participants, if clinically indicated, diagnostic and other tests
could be requested (excluding CD4/total lymphocytes in CDM)
and concomitant medications prescribed. VLs were not performed
in real-time, but were measured retrospectively on stored plasma
samples using Roche Amplicor v1.5.
Participants could substitute alternative antiretrovirals from the
nucleoside reverse transcriptase inhibitor (NRTI)/non-NRTI
classes in first-line regimens for toxicity, TB-treatment or other
reasons; these substitutions did not count as first-line failures. The
decision to switch to a second-line bPI-containing regimen for
first-line failure was based on clinical criteria in both groups (new/
recurrent WHO 4 event (per-protocol); or single or multiple WHO
3 events at clinician discretion), or confirmed CD4,100 cells/
mm3 on ART (,50 cells/mm3 before July 2006) for LCM.
Switching was discouraged before 48 weeks on first-line. Clini-
cian’s decision to switch also took account of adherence and social
circumstances, following standard clinical practice. VL at switch
was assayed in all participants enrolling in nested second-line
studies from 2007 onwards[7,8], plus a random sample of other
second-line switches (including switches during 2004–2006; 85%
assayed on day of switch, 93% within 4 weeks, all within 4 months
previously). 336/459 (73%) participants switching after 1 January
2007 chose to join one or both studies. As per the DART protocol,
all reported WHO 4 events (but not WHO 3 events) were
reviewed against pre-specified criteria by an independent End-
point Review Committee(ERC) blinded to randomised allocation.
This was done retrospectively and did not impact clinical decision-
making.
Statistical analysis
Switch from first- to second-line ART for clinical or immuno-
logical failure (the latter only in LCM participants being managed
using routine CD4 counts) was the primary outcome of interest.
Participants were followed under CDM/LCM strategies until 31
December 2008; this analysis includes only switches to this
timepoint and is an exploratory analysis of trial data not specified
in the original trial protocol. We used Kaplan-Meier methods to
evaluate the time delay from first meeting WHO 4 criteria for
switch (in all patients with WHO 4 events after 44 weeks on ART,
see below), and actual change in regimen. Although the protocol
discouraged switching before 48 weeks, we chose 44 weeks as the
cut-off for this analysis to include a small number of patients who
switched just before 48 weeks because they returned early for their
48 week visit. The secondary outcome was mortality following
switch to second-line. Main exposures considered in those who
switched were reported reason for switching, CD4 and VL at
switch. Analyses of VL included all available VL which had been
measured retrospectively on a subset of participants (see above).
Where LCM participants met both immunological (CD4,100
cells/mm3) and clinical failure criteria, they were counted as
immunological failures. Where CDM participants had both WHO
4 and WHO 3 events, they were counted as WHO 4 failures.
Categorical variables were compared using chi-squared/exact
tests, continuous variables using t-tests/rank-sum tests. To inform
clinical practice when ‘tiebreaker’ VL tests are not available to
confirm that clinical/immunological failure has occurred with
detectable VL[2], we used receiver-operating-characteristic (ROC)
curves to identify the most sensitive and specific (equal weighting)
CD4 threshold cut-off for detecting suppressed VL at the point of
clinical/immunological first-line failure.
Results
Patients monitored clinically without CD4 (or VL) results
1660 CDM participants initiated ART with median(IQR) CD4
86(31–139) cells/mm3 and were clinically monitored without CD4
counts for median 5 years. 314(19%) switched to bPI-containing
second-line for first-line failure after median(IQR) 3.4(2.5–4.2)
years on first-line (only 2 before 48 weeks when switching was
discouraged, both at 46 weeks). In those who switched,
median(IQR) pre-ART CD4 was 47(14–104) cells/mm3 and age
at switch 39(34–44) years; 193(61%) were female.
223(13%) CDM participants had new/recurrent WHO 4 events
accepted by the ERC after 44 weeks on ART: 187/223 (84%)
switched to second-line, 14(6%) died on first-line before switching
and 22(10%) had not switched before trial closure. The Kaplan-
Meier median(IQR) time to switch after meeting failure criteria
was 7(1–23) weeks. The most commonly reported reasons for
delaying switch for .8 weeks/not switching were that the WHO 4
event was judged unrelated to ART failure by the clinician (45%)
or because of drug-drug interactions between rifampicin and bPI
(32%) (Table 1; n= 44). An additional 20 patients switched to
second-line for WHO 4 events eventually judged not to meet pre-
defined protocol criteria by the ERC, leading to a total 207/314
(66%) switches in CDM being for WHO 4 events.
In the same period, 70 multiple (within 60 days) and 392 single
WHO 3 events were reported in participants not switching for
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WHO 4 events. Clinicians used clinical judgement to assess which
of these events were likely first-line ART failure, leading to
30(10%) and 77(25%) of the 314 CDM switches being for multiple
or single WHO 3 events respectively (Table 2). More switches for
multiple/single WHO 3 events occurred over calendar time
(2004–2008) reflecting wider promotion of WHO 3 events as
switch criteria in WHO 2006 guidelines[9]; eg 85% of pre-2007
switches were due to WHO 4 events compared to 53%
subsequently.
CD4 counts were performed 12-weekly in all CDM partici-
pants, but, as not returned, did not influence the decision to
switch. Although the median(IQR) CD4 count at switch was
56(15–196), 64(20%) participants had CD4 $250 cells/mm3
(Table 2). Switching for failure determined by a single WHO 3
event was significantly more likely to occur with CD4$250 cells/
mm3 (36%) compared to multiple WHO 3 (10%) or WHO 4
(16%) events (p = 0.0002).
Most WHO 4 events triggering switch had relatively similar
proportions with CD4$250 cells/mm3 and ,50 cells/mm3
(Table 3), with the exception of cryptococcal meningitis, where
one third (11 events) triggered switch with CD4$250 cells/mm3.
Interestingly CD4 was $250 cells/mm3 in three of the four
switches to second-line triggered by lymphoma. Although gener-
ally considered a less severe WHO 4 event, median(IQR) CD4 at
switch triggered by oesophageal candidiasis was only 30(8–68)
cells/mm3. Weight loss, severe bacterial infection (SBI) and
diarrhoea were the main single WHO 3 events triggering switch
with CD4$250 cells/mm3 (44%, 43% and 100% respectively),
likely reflecting their frequency in adults irrespective of HIV status
or CD4. However, combinations of $2 WHO 3 events triggered
switch at lower CD4 counts, similar to WHO 4 events.
CDM participants switching with WHO 4 events were more
likely to die within a year of switch than those switching with
multiple or single WHO 3, consistent with their severity (19%
versus 3% versus 5% respectively, exact p = 0.002, Table 2).
Interestingly, subsequent mortality was similar in those switching
at high and lower CD4 counts: 17% (11/64) CDM participants
switching with CD4$250 cells/mm3 died within a year of switch
versus 13% (33/250) switching with CD4,250 cells/mm3
(p = 0.41, p = 0.51 adjusted for WHO 3/4 events); and 27% (9/
33) CDM participants switching for WHO 4 events with
CD4$250 cells/mm3 died within 1 year versus 17% (30/174)
with CD4# 250 cells/mm3 (p = 0.22).
Overall 181(58%) CDM participants had VL at switch to
second-line assayed retrospectively. 49(27%) had VL,400 copies/
ml, with similar proportions across reasons for triggering switch
(p = 0.29) (Table 2). Thus 3.7 ‘tie-breaker’ VL tests at clinical
failure would be needed to prevent one switch with suppressed VL.
There was a very wide range of VLs in clinically-monitored
participants failing and switching with CD4,100 cells/mm3
(Figure 1(a)). In contrast, most with CD4.250 cells/mm3 had
suppressed VL.
To inform practice where VL testing is unavailable or
performed off-site (when return of results may be delayed
considerably), we evaluated the predictive ability of a single tie-
breaker CD4 count at clinically-triggered switch to identify
participants with VL,400 copies/ml, using data on VLs assayed
retrospectively on stored samples and CD4 counts which had not
been returned to clinicians. VL was ,400 copies/ml in 38/
48(79%) with CD4$250 cells/mm3 versus only 11/133(8%) with
CD4,250 cells/mm3 (p,0.0001). The area under the receiver-
operating-characteristic (ROC) curve (Figure 2(a)) was 0.91 (95%
CI 0.86–0.96), with an optimal threshold where most observations
Table 1. Reasons for not switching when first met immunological/clinical criteria for switch in patients receiving and not receiving
CD4 monitoring.
CD4 monitoring (LCM) No CD4 monitoring (CDM)
Total met clinical (WHO 4 event) or immunological (confirmed CD4,100 cells/mm3)
criteria for switch and either switched .8 weeks later or did not switch
132 (100%)
Total met clinical criteria (WHO 4 event) for switch and either switched .8 weeks later or did not switch 100 (100%)
Reason for not initially switching patient reported (details below)* 42 (32%) 44 (44%)
No reason reported but switched within 6 months 56 (42%) 33 (33%)
Reason not reported, not switched within 6 months 34 (26%) 23 (23%)
Switched after 6 months 27 21
Died or last seen alive and not switched 7 2
Reason for not switching when first met criteria (% of those reporting a reason) 42 (100%) 44 (100%)
Patient judged to be doing well 30 (71%) 20 (45%)
CD4.200 19 N/A
CD4 100-200 or ,100 but still increasing 9 N/A
only been on ART for ,1 year 0 3
clinical judgement that event not related to ART failure ** 2 12
client felt well and did not want to switch 0 5
On TB treatment with rifampicin 10 (24%) 14 (32%)
Poor adherer/defaulter 1 (2%) 4 (9%)
Too ill to switch 0 (0%) 4 (9%)
Oversight: should have switched 1 (2%) 2 (5%)
*based on a retrospective request for reasons why patients had not switched within 8 weeks of first meeting protocol switch criteria.
**eg only presumptive diagnosis, responded to treatment for the clinical event, event judged related to recent period off ART, patient being monitored and doing well.
doi:10.1371/journal.pone.0057580.t001
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were correctly classified (90%) of CD4$220 cells/mm3. This
cutoff had 86% sensitivity, 92% specificity, 79% positive predictive
value and 95% negative predictive value for identifying partici-
pants with VL,400 copies/ml (LR+=10.3, LR- = 0.16). ROC
areas were similar according to reason for switch and in those
joining and not joining second-line studies (Table 2). Therefore a
threshold of .250 cells/mm3, a close but more likely cut-off for a
CD4 point-of-care assay, would capture most individuals without
virological failure, for whom switching could be premature and
unnecessary.
Patients monitored clinically with 12-weekly CD4 but no
VL results
1656 LCM participants initiated ART with median(IQR) CD4
86(32–140) cells/mm3 and were clinically monitored together with
12-weekly CD4 counts for median 5 years. 361(22%) switched to
bPI-containing second-line for first-line failure after a media-
n(IQR) 2.8(2.1–3.8) years on first-line (shorter than in CDM,
p= 0.0001) (only 1 ,48 weeks). In those who switched,
median(IQR) pre-ART CD4 was 42(17–85) cells/mm3 and age
at switch 39(34–45) years; 201(57%) were female.
326(20%) had a new/recurrent WHO 4 event accepted by the
ERC or met immunological failure criteria after the first 44 weeks
on ART. 286/326 (88%) switched to second-line, 6(2%) died on
first-line before switching and 34(10%) had not switched before
trial closure. The Kaplan-Meier median(IQR) time to switch after
meeting the criteria was 4(2–20) weeks, similar to CDM (p= 0.70).
The most commonly reported reasons for delaying switch for .8
weeks or not switching was high CD4s (71%) or because of drug-
drug interactions between rifampicin and bPI (24%) (Table 1;
n = 42). An additional 75 participants switched to second-line
ART for WHO 4 events not judged to meet pre-defined protocol
criteria by the ERC, single/multiple WHO 3 events or other
CD4-related reasons.
As expected, since CD4 decline generally precedes development
of WHO 4 events, most (73%, 265/361) LCM participants who
switched failed by the CD4,100 cells/mm3 protocol criteria. An
additional 37(10%) switched for WHO 4 events; 43(12%) for other
CD4 reasons (mainly rapid CD4 decline to .100 cells/mm3); and
only 6(2%) and 10(3%) with multiple or single WHO 3 events
respectively (Table 4). Over time, more switches occurred for
CD4s which were low but $100 cells/mm3; for example, 2% pre-
2007 switches were due to CD4 $100 cells/mm3 compared to
24% subsequently, reflecting changes in WHO2006 guidelines[8].
The median(IQR) CD4 count at switch was 63(36–95) cells/
mm3. In contrast to CDM participants, but reflecting clinician
reluctance to switch LCM participants with WHO events and high
CD4s (Table 1), only 7(2%) CD4-monitored participants switched
with CD4$250 cells/mm3 (3 for WHO 4; 1 single WHO 3; 3
other CD4 reasons, all in participants with substantial prior CD4
variability). Mortality following switch was highest in participants
who switched for WHO 4 events before meeting immunological
failure criteria (32% (12/37); p,0.0001)
Overall 187(52%) participants had VL at second-line switch
assayed retrospectively. 23(12%) had VL,400 copies/ml (Table 4;
p,0.0001 versus CDM). Thus 8.1 ‘tie-breaker’ VL tests at
immunological/clinical failure would be needed to prevent one
switch with suppressed VL. Fewer participants switching for
CD4,100 cells/mm3 had VL,400 copies/ml (7%) than those
meeting other CD4 or clinical criteria (p = 0.03). Those with
CD4,100 cells/mm3 had a very wide range of VLs (Figure 1(b)),
similarly to participants monitored without CD4s.
In those receiving 12-weekly CD4 counts, CD4 at switch was a
much poorer predictor of suppressed VL (Figure 2(b)); with area
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under the LCM ROC curve 0.70 (95% CI 0.58–0.73) (similar
according to reason for switch and participation in second-line
studies). This may be because only 14(4%) had CD4 above the
optimal threshold of 220 cells/mm3 for identifying VL suppression
found in CDM, since those LCM participants with high CD4, in
whom VL was more likely suppressed, were rarely switched by
clinicians (Table 1). In fact, 54% (13/24) of LCM participants who
switched with VL,400 copies/ml actually had CD4,110 cells/
mm3 (Figure 1(b)) (median(range) 3.4(1.1–4.9) years on first-line),
highlighting that completely accurate CD4-based prediction of
suppressed VL is impossible.
Interestingly, irrespective of monitoring strategy, virological-
responders/immunological-non-responders with VL,400 copies/
ml but CD4,110 cells/mm3 had excellent response to bPI-
containing second-line ART. In 14 participants (10LCM,4CDM)
the median(IQR) CD4 increase 24 weeks after switching was +129
(+42,+216) cells/mm3 from median(IQR) 70(38–94) cells/mm3 at
switch (4 others (3LCM,1CDM) died before 24 weeks on second-
line).
Discussion
Most public sector ART clinics in low-income settings have very
limited laboratory capacity to monitor patients on therapy, so
justifying and prioritising services provided to support clinical
monitoring is critical. DART has already shown that routine CD4
monitoring alone from the second year of ART has a small but
important impact on survival[4]. WHO recommends the use of
VLs to confirm immunological/clinical failure[2]. Currently,
neither are widely accessible; eg in April-June 2011, there were
only 50 functional CD4 machines in 449 ART clinics in
Malawi[10] and in early 2012, only 4/59 ART centres in Malawi,
Zimbabwe, Uganda, including hospitals, had the possibility to
monitor VL, including off-site[3]; even if theoretically functional,
lack of electricity/consumables/personnel may further reduce
their availability in practice. Further analysis of the unique group
of DART participants failing first-line ART who were clinically-
monitored without routine CD4/VL tests, but with retrospective
CD4 and VLs available, now shows the utility of multiple, but not
single, WHO 3 events as clinical failure criteria in the absence of
any CD4 monitoring; and that, where access to single CD4 tests is
available, a CD4 tiebreaker at a 250 cells/mm3 threshold could
identify ,80% of those failing clinically with VL,400 copies/ml
Table 3. Clinical events triggering switch after 44 weeks on ART in patients monitored without CD4 cell counts (CDM).
No CD4 monitoring (CDM)
Clinical events triggering switch after 44
weeks on ART
N[accepted by ERC]
(%) Median (IQR) CD4
n$250 cells/
mm3(%)
n,50 cells/
mm3(%)
n died within 1
year of switch(%)
WHO 4 207 (100%) 47 (15–165) 33(16%) 105(51%) 39(19%)
Oesophageal candidiasis 76 [70] (37%) 30 (8–68) 3(4%) 47(62%) 8(11%)
Cryptococcal meningitis 33 [28] (16%) 70 (16–270) 11(33%) 15(45%) 11(33%)
Extra–pulmonary TB 26 [22] (13%) 78 (23–188) 3 (12%) 9 (35%) 5 (19%)
HIV wasting 23 [17] (11%) 58 (12–149) 4 (17%) 9 (39%) 7 (30%)
Herpes simplex, mucotaneous 14 [10] (7%) 30 (16–242) 3 (21%) 8 (57%) 2 (14%)
Cryptosporidiosis 13 [12] (6%) 30 (18–203) 3 (23%) 8 (62%) 1 (8%)
PCP 7 [3] (3%) 17 (5–72) 0 (0%) 5 (71%) 1 (14%)
Lymphoma 4 [3] (2%) 373 (178–460) 3 (75%) 1 (25%) 3 (75%)
KS 4 [3] (2%) 149 (66–244) 1 (25%) 1 (25%) 1 (25%)
Toxoplasmosis 2 [2] (1%) 28 (5,52) 0 (0%) 1 (50%) 0 (0%)
CMV 2 [2] (1%) 410 (244,575) 1 (50%) 0 (0%) 0 (0%)
Multiple WHO 3 30 (100%) 19 (9–79) 3 (10%) 18 (60%) 1 (3%)
Weight loss, oral candida 12 (40%) 12 (9–57) 1 (8%) 8 (67%) 1 (8%)
Weight loss, SBI 6 (20%) 54 (10–71) 0 (0%) 3 (50%) 0 (0%)
Oral candida, SBI 4 (13%) 26 (14–166) 1 (25%) 3 (75%) 0 (0%)
Oral candida, pulmonary TB 2 (7%) 8 (3,13) 0 (0%) 2 (100%) 0 (0%)
Multiple SBI 2 (7%) 116 (79,153) 0 (0%) 0 (0%) 0 (0%)
Single WHO3 77 (100%) 102 (23–364) 28 (36%) 28 (36%) 4 (5%)
Weight loss 41 (53%) 224 (37–409) 18 (44%) 11 (27%) 1 (2%)
Oral candida 20 (26%) 31 (12–138) 4 (20%) 12 (60%) 0 (0%)
SBI 7 (9%) 55 (19–303) 3 (43%) 3 (43%) 1 (14%)
Pulmonary TB 5 (6%) 71 (27–98) 1 (20%) 2 (40%) 0 (0%)
Diarrhoea 2 (3%) 490 (327,652) 2 (100%) 0 (0%) 1 (50%)
Note: SBI = severe bacterial infection; OHL =oral hairy leukoplakia; ERC= Endpoint Review Committee (blinded to randomised group). Data not shown for events with
only 1 associated switch: visceral herpes simplex, HIV encephalopathy, recurrent pneumonia, weight loss+persistent fever, weight loss+oral candida+SBI, oral
candida+OHL, pulmonary TB+SBI, HIV nephropathy, OHL). Additional new/recurrent WHO events which occurred during the first year on ART are included in the main
trial report[4], but not here as switch to second-line for first-line failure only occurred after 1 year.
doi:10.1371/journal.pone.0057580.t003
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who may be unlikely to benefit from switching to more costly
second-line therapy.
Despite WHO recommendations to use a VL ‘tie-breaker’ test
to confirm clinical/immunological failure[2], access to expensive
HIV RNA testing is unlikely to improve soon given the current
financial crisis. Point-of-care VL testing could dramatically change
this, but is unlikely to become available for several years, and may
still be relatively costly. Meanwhile, many public sector ART
programmes will continue to monitor ART patients with
negligible access to VL. In contrast, CD4 testing is more widely
accessible[3], and point-of-care devices already in evaluation will
soon increase coverage[11]. However, the sheer volume of testing
will remain challenging, as evidenced by stockouts even of simple
HIV tests[3] and given the 6.6 million adults/children receiving
ART in low/middle-income settings[12]. Making routine CD4
monitoring available to all would require significant additional
investments in laboratory infrastructure, personnel and consum-
ables, which may not be possible given the current financial
situation, particularly as, at current costs, it is not cost-effective for
most African countries[13,14], and a more pressing priority is to
rollout ART to more who need it. Additional benefits of routine
VL over CD4 monitoring are small[15,16] or negligible[17] and
even less cost-effective[18]. It is therefore essential to consider
parsimonious ways to use CD4 testing without VLs to support
clinical monitoring in the critical decision of when to switch to
second-line.
Figure 1. VL and CD4 at switch to second-line for first-line
failure in patients receiving and not receiving CD4 count
monitoring. (a) in patients not receiving routine CD4 count
monitoring (CDM: 20% .250 cells/mm3). (b) in patients receiving
routine CD4 count monitoring (LCM: 2% .250 cells/mm3). Footnote 1
Points at .750000 and ,400 have a small amount of ‘jitter’ added so
that all observations are visible.
doi:10.1371/journal.pone.0057580.g001
Figure 2. Ability of a single CD4 at switch to second-line for
first-line failure to predict VL. (a) in patients not receiving routine
CD4 count monitoring (CDM: 20% .250 cells/mm3). (b) in patients
receiving routine CD4 count monitoring (LCM: 2% .250 cells/mm3).
Footnote 2 Receiver operator curves (ROC) show how the sensitivity
and specificity of CD4 thresholds for predicting VL,400 copies/ml
varies as CD4 increases from 1 to 788 (CDM) or 505 (LCM) cells/mm3.
The straight line indicates performance no better than chance. The
threshold with the greatest probability of correctly classifying each CD4
count according to whether it has VL,400 copies/ml or not is indicated
with sensitivity (proportion with VL,400 c/ml who have CD4$thres-
hold), specificity (proportion with VL$400 c/ml who have CD4
,threshold), positive predictive value (proportion of patients with
CD4 $threshold who have VL,400 c/ml) and negative predictive value
(proportion of patients with CD4 ,threshold who have VL$400 c/ml).
doi:10.1371/journal.pone.0057580.g002
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As our analysis investigated characteristics of those patients
switched to second-line, we did not (and cannot) estimate the
overall accuracy of CD4 (or clinical) criteria for identifying
virological failure in all individuals on treatment. However, our
data clearly confirm that monitoring for clinical failure alone over-
identifies immunological failure, potentially resulting in unneces-
sary and premature switching to more costly second-line
ART[14,19]: 20% of clinical failures/switches had CD4.250
cells/mm3. The low CD4 nadir in DART participants (10% had
pre-ART CD4,10 cells/mm3) may have contributed to this, with
patients at long-term risk for events such as lymphoma, despite
immune reconstitution. Furthermore, 12% of CD4-monitored and
27% of clinically-monitored participants had suppressed VL at
failure/switch, as previously reported[19-22]. Discordance be-
tween clinical, immunological and virological failure at any single
timepoint is expected, as they track different processes. Nor is
failure always absolute: eg 50% of patients with virological failure
and genotypic NNRTI resistance in one South African cohort re-
suppressed while receiving an NNRTI[23]. In resource-limited
settings with access to single confirmatory laboratory tests, the
challenge of how to deal practically with discordance remains.
Whilst relatively short periods on ART leading to incomplete
immune reconstitution may account for some discrepancies in
previous studies[19,20], the 18 participants switching with
CD4,110 cells/mm3 and VL,400 copies/ml in DART had
been on first-line ART for median 3.4 years. Some had variable
CD4 responses on first-line, with periods of low CD4 without
documented non-adherence; others had never responded immu-
nologically, similarly to Kantor et al where 3/7 patients with
persistent CD4,100 cells/mm3 had undetectable VL[20]. Most
DART participants with VL,400 copies/ml but very low CD4 at
failure benefited considerably immunologically from second-line
switch; however 22% (4/18) died shortly after switching. Given
increased mortality risks at CD4,100 cells/mm3 even with
suppressed VL in resource-rich[24,25] and resource-limited
settings[26], there may be clinical benefits from switching this
specific group of discordant responders with very low CD4 from
an NRTI/NNRTI-based first-line to a bPI-based second-line
regimen. Of interest, we also observed relatively high mortality in
participants switching with high CD4 counts and WHO 4 events,
possibly reflecting that developing such events despite apparently
high absolute CD4 counts may indicate underlying functional
immune deficits that may themselves impact mortality risk.
Those ‘failing ART’ clinically with only single WHO 3 events
can be viewed in two ways. The fact that nearly 40% had
CD4.250 cells/mm3 and 33% VL,400 copies/ml demonstrates
lack of sensitivity of these events for ART failure, probably because
of their frequency in the underlying population irrespective of HIV
status. Whilst our results suggest single WHO 3 events should not
trigger switch in isolation, conversely 64% of this group had
CD4#250 cells/mm3 and 67% VL.400 copies/ml, greater than
the wider population on first-line. Targeting them for confirma-
tory tiebreak CD4 testing could therefore identify additional ART
failures whilst avoiding premature switching. Of note, participants
switching with multiple WHO 3 events had lower CD4 and higher
VL at switch than single WHO 3 events. Adding WHO 3 (single
or multiple) events to the WHO 4 criteria for clinical failure
increased the numbers identified by about 50%.
One potential limitation of our study is that clinical monitoring
was conducted by nurses and clinicians in relatively well-
supported, staffed and supervised sites with no ART stock-outs.
DART had excellent retention (just 7% loss to follow-up over five
years) and 5-year survival (87% CDM, 90% LCM). Among
participants randomised to CDM, CD4s were measured but not
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returned and health-workers remained blinded to CD4s through-
out the trial. This enabled us to perform analyses impossible
outside a trial design such as DART. Whilst several WHO 4 events
triggering switch in DART were not considered to meet criteria
for trial endpoints on independent review, we included them in
these analyses. In ART programmes, more WHO 3/4 events
might be over-diagnosed (with clinicians conservatively ascribing
clinical episodes as WHO 3/4 events), but these would likely occur
with high CD4 and VL,400 copies/ml supporting generalisa-
bility of our findings. DART participants were severely immune-
compromised (median 86 cells/mm3) when initiating ART:
generalizability to programmes initiating ART earlier is unknown.
However, such patients would take longer to fail on first-line
therapy, and therefore it is plausible that a greater (rather than
smaller) proportion of clinical events on first-line would be single
WHO 3 rather than multiple WHO 3 or 4 events, in whom we
found greatest VL suppression. Our findings may therefore be
more, rather than less generalizable, to such settings.
The DART protocol only included one of the three WHO
immunological failure criteria (confirmed ,100 cells/mm3) for
LCM participants (although a small number of participants
switched for other CD4 concerns before this). The other criteria
require a series of CD4s (50% decline from peak) or a pre-ART
CD4 (drop below pre-ART baseline) and were not included in the
protocol because they were judged impractical in settings with
limited access to CD4 testing and are anyway not validated; it was
considered that switching should be determined only by known
predictors of mortality on ART (ie overall CD4, not declines or
drops below baseline). These other immunological failure criteria
also generally lead to switch at higher CD4 counts and might be
expected to be associated with higher rates of VL suppression at
switch than demonstrated here, but we cannot assess this. In
addition, as real-time VL monitoring was not performed, we
cannot evaluate the VL.5000 copies/ml WHO criteria for
switching without immunological or clinical failure[2], nor
investigate the performance of CD4 criteria in identifying this
threshold value. Figure 1 shows that most participants switching
for immunological/clinical failure with VL.400 copies/ml had
values around or above this threshold.
The unique opportunity afforded by the DART trial design to
evaluate the value of using CD4 testing parsimoniously to support
clinical monitoring when VL monitoring is unavailable, provides
clear evidence that a single CD4 tie-breaker at clinical failure with
a 250 cells/mm3 threshold can identify patients who have
suppressed VL, providing the potential to reduce unnecessary
switching to costly second-line ART. Adding a single CD4 count
in those failing clinically could therefore improve the specificity
(and positive predictive value) of clinically identified failure for
virological failure: clearly a single count cannot improve the
sensitivity for detecting virological failure in patients without
clinical events. Our results further suggests that multiple (but not
single) WHO 3 events should be considered as well as WHO 4
events in the definition of clinical failure when CD4 testing is
unavailable. If limited CD4 testing is possible, targeting this to
patients with a single WHO stage 3 event could identify additional
failures with detectable VL whilst still avoiding premature, costly
switching to second-line. Programmes in low-income countries
that are considering how to scale-up laboratory services to
rationally support regular clinical follow-up can use these results
to plan how to widen access to CD4 monitoring taking advantage
of new point-of-care technologies.
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